SOURCE: Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc.

September 04, 2013 13:53 ET

Plandai Biotechnology, Inc.'s Phytofare Could Address Growing Diabetes Numbers

NEW YORK, NY--(Marketwired - Sep 4, 2013) - Plandaí Biotechnology, Inc. (OTCQB: PLPL) is already hard at work in Africa to develop a treatment for malaria, and it may just have a product in its Phytofare™ Catechin Complex that can address the continent's diabetes epidemic as well. With diabetes dramatically on the rise worldwide, the numbers are grim everywhere and no country, region or continent is being spared from the disease. 

According to the International Diabetes Federation there are more than 370 million diabetics worldwide and another 190 million who are living with the disease but remain undiagnosed. 

The World Health Organization expects that by 2020 the largest increases in non-communicable disease deaths like cancer and diabetes will be seen in Africa. Professor Bongani Mayosi, the head of medicine at Groote Schuur Hospital in South Africa, said Africa's diabetes statistics are alarming. "In 2008, the continent had 27-million diabetics, or 7.5% of the world's total diabetes population; by 2030 that figure is expected to reach 50-million."

Enter Plandaí Biotechnology, a producer of highly bioavailable plant extracts for industries including health, wellness, nutraceutical, and pharmaceutical, and a company that has set up shop in South Africa to deliver highly bioavailable products to market. In 2011, Plandaí, through its subsidiaries, entered into a 49-year notarial lease on 8,000 acres of tea plantation in Mpumalanga province of South Africa. 

The lease gives Plandaí access to green tea, and other fruits for use in its botanical extracts. This is essential because the company's extraction process is the key to delivering highly bioavailable products and that process requires the use of "live" plant material -- meaning the plant matter must be processed within hours of harvest.

Plandaí feels it is producing products that can make a difference in the fight against diabetes. The company's Phytofare™ Catechin Complex is one of those candidates.

Continue Reading at:

About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Reports, CEO Interviews and Feature Articles. For more information:

Contact Information